Duramycin is a cyclic peptide lantibiotic derived from Streptomyces cinnamoneuma. Duramycin interacts with phosphatidylethanolamine (PE) and has antibacterial, antiviral effects. Duramycin stimulates chloride secretion in airway epithelium and has the potential for cystic fibrosis treatment.

Duramycin affects protein-lipid interactions, impairs protein translocation, induces aggregation of lipid vesicles, and inhibits ATP-dependent Ca2+ uptake by the sarcoplasmic reticulum.

[68Ga]NODAGA-Duramycin PET/CT is successfully applied to non-invasively detect chemotherapy-induced organ toxicity with high sensitivity in mice.Evaluation of [68Ga]NODAGA-Duramycin as a positron emission tomography (PET) tracer of cell death for whole-body detection of chemotherapy-induced organ toxicity. Organ uptake is analyzed in untreated and doxorubicin, busulfan, and cisplatin-treated mice 2 h after intravenous injection of [68Ga]NODAGA-Duramycin.

1391-36-2

C89H125N23O25S3

2013.28

Moli1901;Lancovutide;Duramycin

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years